

Guidelines at-a-Glance

ADAPTED FROM

Morgenthaler TI; Kapur VK; Brown TM; Swick TJ; Alessi C; Aurora RN; Boehlecke B; Chesson AL; Friedman L; Maganti R; Owens J; Pancer J; Zak R; Standards of Practice Committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. *SLEEP* 2007;30(12):1705-1711 Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin

AASM LEVELS OF RECOMMENDATIONS

TERM	DEFINITION
STANDARD	This is a generally accepted patient-care strategy, which reflects a high degree of clinical certainty. The term standard generally implies the use of Level I Evidence, which directly addresses the clinical issue, or overwhelming Level II Evidence.
GUIDELINE	This is a patient-care strategy, which reflects a moderate degree of clinical certainty. The term guideline implies the use of Level II Evidence or a consensus of Level III Evidence.
OPTION	This is a patient-care strategy, which reflects uncertain clinical use. The term option implies either inconclusive or conflicting evidence or conflicting expert opinion.

GENERAL RECOMMENDATIONS

An accurate diagnosis of a specific hypersomnia disorder of central origin should be established. The evaluation should include a thorough evaluation of other possible contributing causes of excessive daytime sleepiness.

Treatment objectives should include control of sleepiness and other sleep related symptoms when present.

RECOMMENDATIONS FOR TREATING NARCOLEPSY

3a	Modafinil is effective for treatment of daytime sleepiness due to narcolepsy	STANDARD
3b	Sodium oxybate is effective for treatment of cataplexy, daytime sleepiness, and disrupted sleep due to narcolepsy	STANDARD
	Sodium oxybate may be effective for treatment of hypnagogic hallucinations and sleep paralysis	OPTION
3c	Amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are effective for treatment of daytime sleepiness due to narcolepsy	GUIDELINE
3d	Selegiline may be an effective treatment for cataplexy and daytime sleepiness.	OPTION
3e	Ritanserin may be effective treatment of daytime sleepiness due to narcolepsy	OPTION

RECOMMENDATIONS FOR TREATING NARCOLEPSY (CONTINUED)

Pemoline has rare but potentially lethal liver toxicity, is no longer available oPTION in the United States, and is no longer recommended for treatment of narcolepsy

Tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), GUIDELINE venlafaxine, and reboxetine may be effective treatment for cataplexy

Tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and venlafaxine may be effective treatment for treatment of sleep paralysis and hypnagogic hallucinations.

OPTION

RECOMMENDATIONS FOR TREATING IDIOPATHIC HYPERSOMNIA

4 Modafinil may be effective for treatment of daytime sleepiness due to idiopathic hypersomnia.

OPTION

7 The following medications may be effective for treatment of daytime sleepiness in idiopathic hypersomnia (with and without long sleep time), recurrent hypersomnia, and hypersomnia due to a medical condition: amphetamine, methamphetamine, dextroamphetamine, methylphenidate, and modafinil.

OPTION

RECOMMENDATIONS FOR TREATING SPECIFIC TYPES OF HYPERSOMNIAS DUE TO A MEDICAL CONDITION

Modafinil may be effective for treatment of daytime sleepiness due to OPTION Parkinson's disease.

5b Modafinil may be effective for treatment of daytime sleepiness due to OPTION myotonic dystrophy.

5c Methylphenidate may be effective for treatment of daytime sleepiness OPTION due to myotonic dystrophy.

5d Modafinil may be effective for treatment of daytime sleepiness due to multiple sclerosis GUIDELINE

7 The following medications may be effective for treatment of daytime sleepiness in idiopathic hypersomnia (with and without long sleep time), recurrent hypersomnia, and hypersomnia due to a medical condition: amphetamine, methamphetamine, dextroamphetamine, methylphenidate, and modafinil.

OPTION

RECOMMENDATIONS FOR TREATING RECURRENT HYPERSOMNIA AND BEHAVIORAL SYMPTOMS DUE TO KLEINE-LEVIN SYNDROME

Lithium carbonate may be effective for treatment of recurrent hypersomnia OPTION and behavioral symptoms due to Kleine-Levin syndrome.

RECOMMENDATIONS FOR TREATING HYPERSOMNIAS OF CENTRAL ORIGIN I

8a Combinations of long- and short-acting forms of stimulants may be indicated and effective for some patients.

OPTION

Treatment of hypersomnias of central origin with methylphenidate or modafinil in children between the ages of 6 and 15 appears to be relatively safe.

OPTION

Regular follow-up of patients with hypersomnia of central origin is necessary to monitor response to treatment, to respond to potential side effects of medications, and to enhance the patient's adaptation to the disorder

STANDARD

RECOMMENDATIONS FOR RECURRING HYPERSOMNIA

7 The following medications may be effective for treatment of daytime sleepiness in idiopathic hypersomnia (with and without long sleep time), recurrent hypersomnia, and hypersomnia due to a medical condition: amphetamine, methamphetamine, dextroamphetamine, methylphenidate, and modafinil.

OPTION